Difference between revisions of "Team:Tianjin/Demonstrate"

Line 231: Line 231:
 
<hr>
 
<hr>
 
   <p>In this pathway, we chose <i>Gal1</i> as our inducible promoter for the expression of <i>HO</i> gene, <i>CYC1</i> as the terminator, and <i>PRS416</i>(with <i>Ura-tag</i>) as our vector. As for segments ligation, we designed the cutting sites for <i>Bsa1</i> enzyme in each part, hoping to achieve seamless ligation of these three parts.</p>
 
   <p>In this pathway, we chose <i>Gal1</i> as our inducible promoter for the expression of <i>HO</i> gene, <i>CYC1</i> as the terminator, and <i>PRS416</i>(with <i>Ura-tag</i>) as our vector. As for segments ligation, we designed the cutting sites for <i>Bsa1</i> enzyme in each part, hoping to achieve seamless ligation of these three parts.</p>
<p>We adopted the PCR method to amplify the <b><i>Gal1-part</i></b> and <b><i>CYC1-part</i></b> from a <i>Gal1-Vika</i> plasmid we had used in our former lab work with specially designed primers for this procedure. After PCR, the <i>Gal1</i> has the cutting sites for <i>SalⅠ</i>and <i>BsaⅠ</i>on both ends, and <i>CYC1</i> has that for <i>BsaⅠ</i>and <i>BamhⅠ</i>on both ends. Meanwhile, the <i>HO</i> gene was obtained by gene synthesis, flanked by specific hangtags for <i>BsaⅠ</i>in order to be cohesive with <i>Gal1</i> (upstream) and <i>CYC1</i> (downstream). Thus, we have built our composite part (<i>GHC</i>).</p>
+
<p>We adopted the PCR method to amplify the <b><i>Gal1-part</i><a href="http://parts.igem.org/Part:BBa_K2407001">BBa_K2407001</a></b> and <b><i>CYC1-part</i><a href="http://parts.igem.org/Part:BBa_K2407107">BBa_K2407107</a></b> from a <i>Gal1-Vika</i> plasmid we had used in our former lab work with specially designed primers for this procedure. After PCR, the <i>Gal1</i> has the cutting sites for <i>SalⅠ</i>and <i>BsaⅠ</i>on both ends, and <i>CYC1</i> has that for <i>BsaⅠ</i>and <i>BamhⅠ</i>on both ends. Meanwhile, the <b><i>HO</i><a href="http://parts.igem.org/Part:BBa_K2407109">BBa_K2407109</a><b> gene was obtained by gene synthesis, flanked by specific hangtags for <i>BsaⅠ</i>in order to be cohesive with <i>Gal1</i> (upstream) and <i>CYC1</i> (downstream). Thus, we have built our composite part (<i>GHC</i>).</p>
<p>After the ligation of<b><i>GHC</i></b> and <i>PRS416</i> Plasmid (<b><i>GHC-416</i></b>), we transformed the E. coli for the augment of our new plasmid——<b><i>GHC-416</i></b>. We examined the transformation result by PCR method to amplify the <i>HO</i> gene in the E. coli which we randomly selected in the plate.   
+
<p>After the ligation of<b><i>GHC</i><a href="http://parts.igem.org/Part:BBa_K2407100">BBa_K2407100</a></b> and <i>PRS416</i> Plasmid (<b><i>GHC-416</i></b>), we transformed the E. coli for the augment of our new plasmid——<b><i>GHC-416</i></b>. We examined the transformation result by PCR method to amplify the <i>HO</i> gene in the E. coli which we randomly selected in the plate.   
 
</p>
 
</p>
 
   <img src="https://static.igem.org/mediawiki/2017/b/b9/Tianjin-ho-result-666.jpeg">
 
   <img src="https://static.igem.org/mediawiki/2017/b/b9/Tianjin-ho-result-666.jpeg">

Revision as of 12:31, 27 October 2017

/* OVERRIDE IGEM SETTINGS */

Demonstrate